Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

14.86

-0.14 (-0.93%)

At close: Nov 6, 2026, 4:00 PM EST

14.82

-0.04 (-0.27%)

After-hours: Nov 6, 2026, 7:46 PM EST

Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	92.05	60.18	105.6	145.65	123.55	293.83
Short-Term Investments	85.05	187.04	264.93	400.58	516.6	320.97
Cash & Short-Term Investments	177.11	247.22	370.53	546.22	640.15	614.79
Cash Growth	-44.59%	-33.28%	-32.17%	-14.67%	4.13%	0.36%
Prepaid Expenses	9.11	13.72	9.07	8.46	11.14	11.49
Total Current Assets	186.21	260.94	379.59	554.69	651.3	626.29
Property, Plant & Equipment	44.26	53.64	72.94	142.32	166.27	166.64
Long-Term Investments	35.88	19	32.01	48.51	115.04	330.53
Other Long-Term Assets	7.5	6.47	6.31	4.52	4.96	3.95
Total Assets	273.85	340.05	490.86	750.03	937.56	1,127

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	4.04	2.89	5.37	4.82	3.92	3.21
Accrued Expenses	31.97	20.94	29.37	20.36	21.14	22.36
Current Portion of Leases	9.97	9.07	7.97	6.27	4.53	1.17
Current Unearned Revenue	-	2.54	0.48	-	-	4.99
Other Current Liabilities	0.3	13.97	10.6	3.07	7.44	15.01
Total Current Liabilities	46.27	49.41	53.79	34.52	37.03	46.74
Long-Term Leases	34.32	41.92	50.99	56.89	63.17	66.65
Long-Term Unearned Revenue	-	-	-	-	-	79.67
Other Long-Term Liabilities	0.55	0.52	3.25	3.66	4.11	4.57
Total Liabilities	81.13	91.85	108.04	95.08	104.31	197.62

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0	0	0	0.03	0.03	0.02
Additional Paid-In Capital	1,927	1,868	1,728	1,657	1,608	1,516
Retained Earnings	-1,734	-1,620	-1,345	-1,002	-767.48	-584.36
Comprehensive Income & Other	-0.28	0.24	0.29	-0.09	-7.6	-1.62
Total Common Equity	192.72	248.2	382.82	654.95	833.25	929.79
Shareholders' Equity	192.72	248.2	382.82	654.95	833.25	929.79
Total Liabilities & Equity	273.85	340.05	490.86	750.03	937.56	1,127

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	44.29	50.99	58.97	63.17	67.7	67.82
Net Cash (Debt)	149.7	196.23	324.57	499.56	642.57	830.51
Net Cash Growth	-43.84%	-39.54%	-35.03%	-22.25%	-22.63%	30.16%
Net Cash Per Share	6.64	11.48	24.83	39.81	52.01	122.21
Filing Date Shares Outstanding	24.59	23.31	14.76	12.7	12.48	12.14
Total Common Shares Outstanding	24.58	21.25	14.74	12.7	12.48	12.14
Working Capital	139.94	211.53	325.81	520.17	614.27	579.55
Book Value Per Share	7.84	11.68	25.97	51.58	66.78	76.61
Tangible Book Value	192.72	248.2	382.82	654.95	833.25	929.79
Tangible Book Value Per Share	7.84	11.68	25.97	51.58	66.78	76.61
Machinery	-	28.86	39.03	35.85	34.33	29.03
Construction In Progress	-	0.45	0.24	0.13	4.15	10.58
Leasehold Improvements	-	79.74	79.61	118.32	116.93	95

SEC Filings: 10-K · 10-Q